MTOR and cancer: Interestingly, patients on mTOR inhibitors, such as sirolimus and everolimus, may exhibit increased radiosensitivity in their cancer cells, which, in turn, would make them more suitable candidates for image-guided hypofractionated or ultra-hypofractionated radiotherapy as a definitive treatment [35].